- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04958798
Culturally Centering Medications for Opioid Use Disorder With American Indian and Alaska Native Communities (CTN-0096)
July 28, 2023 updated by: Aimee Campbell, New York State Psychiatric Institute
Culturally Centering Medications for Opioid Use Disorder With American Indian and Alaska
This is a formative research study to test a culturally-centered, program-level implementation intervention to increase the use of medications for opioid use disorder in four healthcare and addiction specialty treatment sites serving American Indian and Alaska Native communities.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a formative research study to test a culturally-centered, program-level implementation intervention to increase the use of medications for opioid use disorder (MOUD) in four healthcare and addiction specialty treatment sites serving American Indian and Alaska Native communities.
The study design is a cluster randomized stepped wedge implementation trial with two steps, and two sites per step (N=4 sites).
Study design and methods are informed by the Consolidated Framework for Implementation Research (CFIR) and the RE-AIM framework (Reach, Effectiveness, Adoption, Implementation, Maintenance).
The primary outcome of the trial is the number of consumers with OUD initiated onto MOUD (i.e., buprenorphine, extended-release naltrexone, or methadone) in the 6 months after intervention delivery (compared to the 6 months before intervention delivery) - capturing implementation intervention Reach.
The primary outcome will be measured at the end of the six-month implementation stage and compared to the pre-intervention observation phase (prior to delivery of the implementation intervention).
Primary data collection will use de-identified data from the electronic medical records (EMR) at each site beginning with data from the six months prior to intervention delivery for Step 1 sites and 12 months prior for Step 2 sites.
For Step 1 sites, some secondary outcomes will also be assessed during the sustainment stage (the six months following implementation).
As part of the study, consumers with OUD will be asked to participate in additional assessments and provide informed consent.
Enrolled consumer participants will be asked to complete four assessment visits (baseline, week 4, week 8, and week 12) to collect comprehensive information about mental health, cultural connectedness and spirituality, social functioning, and experiences with and acceptability of OUD treatment.
Providers at each clinical site will also be asked to complete surveys at three time points to assess attitudes, knowledge, and readiness related to MOUD.
Study Type
Interventional
Enrollment (Estimated)
200
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Aimee Campbell, PhD
- Phone Number: 6467746138
- Email: anc2002@cumc.columbia.edu
Study Contact Backup
- Name: Margaret Paschen-Wolff, PhD
- Email: Margaret.Paschen-Wolff@nyspi.columbia.edu
Study Locations
-
-
Alaska
-
Anchorage, Alaska, United States, 99508
- Recruiting
- Southcentral Foundation
-
Contact:
- Kelley Jansen
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55404
- Recruiting
- Native American Community Clinic
-
Contact:
- Antony Stately, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Willing and able to provide informed consent
- English comprehension and proficiency
- Receiving services at a participating study site
- Meet criteria for a current opioid use disorder
- Self-identify as American Indian or Alaska Native
- Willing to have program data linked to assessment data
- 18 years or older
Exclusion Criteria:
- participation in research assessments contraindicated
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Culturally Centered MOUD Implementation
Culturally centered program-level implementation intervention to increase the use of medications for opioid use disorder in healthcare and treatment settings serving AI/AN communities
|
Support clinical sites to culturally center the delivery of medications for opioid use disorder through evidence-based implementation strategies tailored to local needs
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
# consumers with OUD initiated onto MOUD
Time Frame: 6 months
|
number of consumers with OUD initiated onto MOUD in the 6 months after intervention delivery compared to pre-intervention
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
# consumers with OUD offered MOUD
Time Frame: 6 months
|
number of consumers with OUD offered MOUD in the 6 months after intervention delivery compared to pre-intervention
|
6 months
|
# consumers screened for OUD of the overall # of new consumers
Time Frame: 6 months
|
number of consumers screened for OUD of the overall number of new consumers in the 6 months after intervention delivery compared to pre-intervention
|
6 months
|
# consumers with OUD retained in care for at least three months
Time Frame: 6 months
|
number of consumers with OUD retained in care for at least three months in the 6 months after intervention delivery compared to pre-intervention
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 21, 2022
Primary Completion (Estimated)
March 31, 2024
Study Completion (Estimated)
May 31, 2024
Study Registration Dates
First Submitted
July 6, 2021
First Submitted That Met QC Criteria
July 6, 2021
First Posted (Actual)
July 12, 2021
Study Record Updates
Last Update Posted (Actual)
August 1, 2023
Last Update Submitted That Met QC Criteria
July 28, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- #8026
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Data from this study is owned by participating Tribal clinical sites; any use of IPD requires Tribal (or equivalent organizational) approval.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid-use Disorder
-
Aurora Health CareUniversity of Chicago; University of California, Santa Cruz; Rogers Behavioral...RecruitingSubstance Use | Methamphetamine-dependence | Opioid Use | Opioid-use Disorder | Cocaine Use Disorder | Cocaine Use | Methamphetamine AbuseUnited States
-
Hennepin Healthcare Research InstituteNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCRecruitingSubstance Use Disorder | Opioid Use Disorder, Moderate | Opioid Use Disorder, SevereUnited States
-
Hennepin Healthcare Research InstituteNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCRecruitingSubstance Use Disorders | Opioid Use Disorder, Moderate | Opioid Use Disorder, SevereUnited States
-
Vanderbilt University Medical CenterCompletedOpioid Use | Opioid-use DisorderUnited States
-
Emory UniversityNational Institute on Drug Abuse (NIDA); Georgia Institute of Technology; CUNYCompletedSubstance-Related Disorders | Substance Abuse, Intravenous | Substance Use Disorders | Opioid Use | Substance Abuse | Opioid-use Disorder | Opioid Use Disorder, Severe | Substance WithdrawalUnited States
-
Albert Einstein College of MedicineNational Institute on Drug Abuse (NIDA); Pfizer; National Institutes of Health...Active, not recruitingTobacco Use Disorder | Opioid-use DisorderUnited States
-
Indiana UniversityCompletedOpioid Use | Opioid-use DisorderUnited States
-
University of ZurichCompletedOpioid Use, Unspecified With Other Opioid-induced DisorderSwitzerland
-
Virginia Commonwealth UniversityNational Institute on Drug Abuse (NIDA)CompletedOpioid-use Disorder | Cocaine Use Disorder | Healthy Controls | Marijuana Use DisorderUnited States
-
New York State Psychiatric InstituteColumbia University; Weill Medical College of Cornell University; National Institute... and other collaboratorsActive, not recruitingOpioid Use | Opioid Court Model | Medication to Treat Opioid Use DisorderUnited States
Clinical Trials on Culturally Centered MOUD Implementation Intervention
-
Michigan State UniversityAmerican Cancer Society, Inc.Enrolling by invitationColorectal CancerUnited States
-
Yale UniversityNational Institute of Allergy and Infectious Diseases (NIAID); National Heart...CompletedTuberculosis | Tuberculosis, PulmonaryUganda
-
University of MontanaNot yet recruitingCoronary Disease | Breast Density | Emphysema or COPD
-
University of Colorado, DenverWashington State University; Missouri Breaks Industries Research, Inc.RecruitingAlzheimer DiseaseUnited States
-
Clalit Health ServicesBen-Gurion University of the NegevUnknownPostpartum Depression
-
University of Illinois at ChicagoUniversity of Chicago; Rush University Medical CenterNot yet recruitingHeart Diseases | Neoplasms | Advance Care Planning
-
Butler HospitalNational Institute on Drug Abuse (NIDA)CompletedHIV Infections | Tobacco DependenceUnited States
-
Hôpital le VinatierRecruitingMental DisordersFrance
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)CompletedTobacco SmokingUnited States
-
Sykehuset Innlandet HFEuropean UnionCompleted